结核病与肺部健康杂志 ›› 2019, Vol. 8 ›› Issue (3): 183-187.doi: 10.3969/j.issn.2095-3755.2019.03.007

• 论著 • 上一篇    下一篇

含卷曲霉素方案治疗MDR-TB患者引起低钾血症的临床分析

马进宝,马婷婷(),任斐,杨虹   

  1. 710100 西安市胸科医院耐药结核科
  • 收稿日期:2019-09-03 出版日期:2019-09-30 发布日期:2019-10-15
  • 通信作者: 马婷婷 E-mail:854810572@qq.com

Analysis of hypokalemia caused by capreomycin in patients with multidrug-resistant tuberculosis

MA Jin-bao,MA Ting-ting(),REN Fei,YANG Hong.   

  1. Xi’an Chest Hospital, Xi’an 710061, China
  • Received:2019-09-03 Online:2019-09-30 Published:2019-10-15
  • Contact: Ting-ting MA E-mail:854810572@qq.com

摘要:

目的 分析含卷曲霉素的化疗方案治疗MDR-TB患者引起低钾血症的临床特点、转归及可能的影响因素。方法 选取2016年1月至2018年1月就诊于西安市胸科医院耐药结核科使用含卷曲霉素方案治疗的MDR-TB患者129例,根据是否出现低钾血症分为低钾组和非低钾组,分别为56例(43.4%)和73例(56.6%);收集两组患者的临床资料,分析患者发生低钾血症的严重程度、发生时间和转归。以出现低钾血症为应变量,对可能的影响因素进行单因素分析。采用SPSS 18.0软件进行统计学分析,计数资料使用χ 2检验,计量资料使用t检验,检验水准α=0.05;将差异有统计学意义的4个变量及肾功能损伤进行多因素逐步logistic回归分析。 结果 (1)卷曲霉素引起低钾血症的轻、中、重度发生率分别为69.6%(39/56)、23.2%(13/56)、7.2%(4/56),在使用卷曲霉素全程均有低钾血症发生,主要发生在前16周[89.3%(50/56)];(2)56例低钾血症患者中52例经补钾治疗后纠正,4例重度低钾血症患者因难以纠正而停用卷曲霉素,停用卷曲霉素后患者逐渐恢复正常;(3)单因素分析显示年龄(χ 2=5.130,P=0.024),体质量指数(χ 2=7.087,P=0.029),糖尿病(χ 2=13.830,P=0.000)、治疗前血清低白蛋白(t=2.150,P=0.034)与发生低钾血症相关(P值均<0.05);多因素分析显示,治疗前血清低白蛋白(Wald χ 2=6.261,P=0.012,OR=0.362),并发糖尿病(Wald χ 2=10.310,P=0.001,OR=6.394)为卷曲霉素引起低钾血症的独立危险因素。 结论 卷曲霉素引起低钾血症发生率较高,使用过程中应全程密切监测电解质;出现低钾血症经补钾治疗后大部分患者仍能继续使用卷曲霉素;低蛋白血症、并发糖尿病是其危险因素。

关键词: 结核, 抗多种药物性, 药物疗法, 联合, 卷曲霉素, 低钾血症, 危险因素, 因素分析, 统计学

Abstract:

Objective To analyze clinical characteristics, prognosis and possible influencing factors of capreomycin-induced hypokalemia in patients with multidrug-resistant tuberculosis.Methods One hundred and twenty-nine patients with MDR-TB treated with capreomycin from January 2016 to January 2018 in Xi’an Chest Hosipital were selected. Among them, 56 (43.4%) patients suffered from capreomycin-induced hypokalemia and 73 (56.6%) patients did not get hypokalemia. The severity, onset time, prognosis of hypokalemia and its possible influencing factors were analyzed. Student’s t test and χ 2 test were used separately to compare the difference of continuous measurements and categorical variables for hypokalemia and non-hypokalemia groups, P-value <0.05 was considered as statistically significant. Logistic regression analysis was done to identify risk factors. All statistical analyses were conducted on a personal computer with the SPSS of windows (version 18.0) software package. Results (1) Incidences of mild, moderate and severe hypokalemia caused by capreomycin were 69.6% (39/56), 23.2% (13/56) and 7.2% (4/56) respectively. Hypokalemia occurred during the whole course of using capreomycin, mainly in the first 16 weeks (89.3%, 50/56). (2) 52 of 56 patients with hypokalemia recovered after receiving potassium supplementation treatment, the other four patients recovered gradually after stopping using capreomycin due to severe hypokalemia. (3) The Univariate analysis revealed that 4 factors were associated with capreomycin-induced hypokalemia: age (χ 2=5.130,P=0.024), body mass index (χ 2=7.087,P=0.029),diabetes (χ 2=13.830, P=0.000) and serum albumin (t=2.150, P=0.034); Taking these factors and whether renal impairment existed into the logistic regression model, the result showed that serum albumin (Wald χ 2=6.261,P=0.012,OR=0.362)and diabetes (Wald χ 2=10.310,P=0.001,OR=6.394) were independent high risk factors for capreomycin-induced hypokalemia. Conclusion The incidence of capreomycin-induced hypokalemia was high. Serum electrolyte should be monitored intensively throughout capreomycin using process. Most patients with hypokalemia could stand to continually using capreomycin after receiving potassium supplementation treatment. Hypoproteinemia, diabetes were risk factors for hypokalemia.

Key words: Tuberculosis, multidrug-resistant, Drug therapy, combination, Capreomycin, Hypokalemia, Risk factors, Factor analysis, statistical